A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B-cell targeted therapy with rituximab in RA. Underlying the statement were data from randomised controlled clinical trials and the vast literature in oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in RA.
- Rheumatoid arthritis
- anti-TNF failure